
Medicina, Год журнала: 2025, Номер 61(4), С. 701 - 701
Опубликована: Апрель 11, 2025
Background and Objectives: Despite ongoing research evolving diagnostic criteria, progressive supranuclear palsy (PSP) corticobasal syndrome (CBS) remain notoriously difficult to differentiate, largely due their overlapping clinical presentations the absence of definitive biomarkers. Materials Methods: We provide a comprehensive review cerebrospinal fluid (CSF) biomarkers, which have proven valuable in diagnosis other neurodegenerative conditions, application PSP CBS. Results: The most promising results derive from combination biomarkers associated with Parkinson’s disease, Alzheimer’s neurofilament light chain. Furthermore, CSF proteomics analysis offers insights into pathogenesis CBS could also contribute accurate diagnosis. Conclusions: hold significant potential for improving differential A stepwise approach—starting α-synuclein chain, followed by amyloid-β42 total phosphorylated tau—may clinicians practical framework distinguishing disorders. To advance this field, future efforts should prioritize large-scale, multicenter studies employing standardized methodologies enhance validity reproducibility biomarker-based diagnostics. Importantly, considering frequent pathological overlap between CBS, would greatly benefit pathology-confirmed cohorts ensure accuracy better delineate biomarker profiles across these challenging conditions.
Язык: Английский